Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial

BACKGROUND: Current treatments for chronic hepatitis B (CHB) include pegylated interferon alpha (PEG-IFN-α) which is an immune modulator, and nucleos(t)ide analogs (NAs) which directly inhibit HBV DNA polymerase. With the limited efficacy of PEG-IFN-α and prolonged treatment periods associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yan, Wang, Xu, Liu, Zhenhua, Zhou, Changyu, Qi, Wenqian, Jiao, Jian, Yu, Fan, Guo, Honghua, Zhao, Ping, Wang, Jiangbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577782/
https://www.ncbi.nlm.nih.gov/pubmed/28854883
http://dx.doi.org/10.1186/s12876-017-0657-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577782/
https://www.ncbi.nlm.nih.gov/pubmed/28854883
http://dx.doi.org/10.1186/s12876-017-0657-y

Ejemplares similares